Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Eagle Pharmaceuticals, Inc. (EGRX)
USD0.60
-0.08 (-11.19%)
US OTC Healthcare Drug Manufacturers - Specialty & Generic
Address
50 Tice Boulevard 7677
Woodcliff Lake, NJ, US
Woodcliff Lake, NJ, US
CEO
Michael Graves
Website
eagleus.com
IPO
2014-02-12
ISIN US2697961082
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company’s product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma. It also produces PEMFEXY, a ready-to-dilute liquid form of pemetrexed injection, indicated in combination with cisplatin for the initial treatment of patients with malignant pleural mesothelioma and non-small cell lung cancer; BARHEMSYS, a selective dopamine-2 (D2) and dopamine-3 (D3) receptor antagonist indicated in adults for prevention of postoperative nausea and vomiting (PONV); BYFAVO, a benzodiazepine indicated for the induction and maintenance of procedural sedation in adults. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an anti-toxin agent in Phase 2 development for the treatment of severe pneumonia in combination with traditional antibacterial drugs; ENA-001 developed by Enalare, an agnostic respiratory stimulant for respiratory depression; EA-114, novel and proprietary formulation of fulvestrant developed for hormone-receptor-positive (HR+) metastatic breast cancer. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat cancer. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.60
-0.08 (-11.19%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
3.9K
Beta
0.66
Float Shares
11.48M
Free Float %
88.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -77.63% | -77.63% | -75.07% | -66.00% | -93.46% | -87.86% | -95.73% | -99.59% | -99.79% | -99.79% | -99.34% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (6 ratings, all time)
Hold
Ratings Trend (MoM)
75% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
1.67
Distress
Piotroski F-Score
4 / 9
Average
MOAT Score
2 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+84.6% ★ Q2'23: -12.8% (vs Q2'22)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+513.6% ★ Q2'23: +152.7% (vs Q2'22)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+9.8% ★ Q2'23: -0.2% (vs Q2'22)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+20.7% ★ Q2'23: +16.6% (vs Q2'22)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+16.0% ★ Q2'23: +8.4% (vs Q2'22)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.1% Q2'23: +2.5% (vs Q2'22)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.87× Q2'23: 1.10× (vs Q2'22)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-9.58M
OE per share TTM
-0.72
Owner's Yield
-861.12%
Maintenance CapEx ratio
2.50%
Maint CapEx / Avg PPE
1.3%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
2
Total invested
4.2K
Insider transactions (90d)
0
Beneficial owners (>5%)
28
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Scott Tarriff | 2.42M | 17.61% | 1.25M | 1.17M | 1.25M | 1.17M | IN | United States | 2022-02-14 | ↗ |
| 2 | (1) BlackRock, Inc. | 1.97M | 15.20% | 1.92M | — | 1.97M | — | HC | Delaware | 2022-01-27 | ↗ |
| 3 | Daniel Mack | 1.96M | 15.10% | — | 1.96M | — | — | HC | MA | 2024-07-03 | ↗ |
| 4 | Nantahala Capital Management, LLC | 1.96M | 15.10% | — | 1.96M | — | — | IA | MA | 2024-07-03 | ↗ |
| 5 | Wilmot B. Harkey | 1.96M | 15.10% | — | 1.96M | — | — | HC | MA | 2024-07-03 | ↗ |
| 6 | EIN #00-0000000 | 1.53M | 11.80% | — | 1.53M | — | 1.53M | IA, HC | Jersey, Channel Islands | 2022-02-10 | ↗ |
| 7 | Leon Zaltzman | 1.19M | 9.17% | — | 1.19M | — | — | IN | Delaware, United States | 2024-10-08 | ↗ |
| 8 | Union Square Park Capital Management, LLC | 1.19M | 9.17% | — | 1.19M | — | — | IA | Delaware, United States | 2024-10-08 | ↗ |
| 9 | Union Square Park GP, LLC | 1.19M | 9.17% | — | 1.19M | — | — | OO | Delaware, United States | 2024-10-08 | ↗ |
| 10 | Union Square Park Partners, LP | 1.19M | 9.17% | — | 1.19M | — | — | PN | Delaware, United States | 2024-10-08 | ↗ |
| 11 | 13G | 1.09M | 11.00% | 100.0K | 992.6K | 100.0K | 992.6K | IN | United States | 2021-02-16 | ↗ |
| 12 | Identification Nos. of above persons (. | 1.06M | 8.20% | 1.06M | — | 1.06M | — | IN | Maryland | 2024-02-07 | ↗ |
| 13 | Citigroup Financial Products Inc. | 1.00M | 7.70% | — | 1.00M | — | 1.00M | CO | — | 2024-11-12 | ↗ |
| 14 | Citigroup Global Markets Holdings Inc. | 1.00M | 7.70% | — | 1.00M | — | 1.00M | HC | — | 2024-11-12 | ↗ |
| 15 | Citigroup Inc. | 1.00M | 7.70% | — | 1.00M | — | 1.00M | HC | — | 2024-11-12 | ↗ |
| 16 | Citigroup Global Markets Inc. | 1.00M | 7.70% | — | 1.00M | — | 1.00M | BD | — | 2024-11-12 | ↗ |
| 17 | Tarriff 2016 Generation Skipping Exempt Family Trust DTD 12/28/2016 | 992.6K | 7.76% | — | 992.6K | — | 992.6K | OO | New Jersey | 2022-02-14 | ↗ |
| 18 | 01-0825912 | 965.8K | 7.50% | — | 965.8K | — | 965.8K | IV | Massachusetts | 2022-02-10 | ↗ |
| 19 | The Vanguard Group - 23-1945930 | 760.5K | 5.89% | — | 17.8K | 734.2K | 26.2K | IA | Pennsylvania | 2022-02-09 | ↗ |
| 20 | 33-0704072 | 745.1K | 5.74% | — | 299.2K | — | 745.1K | IA, PN | Delaware | 2024-02-12 | ↗ |
| 21 | 73-1677697 | 745.1K | 5.74% | — | 299.2K | — | 745.1K | CO, OO | Delaware | 2024-02-12 | ↗ |
| 22 | only). | 745.1K | 5.74% | — | 299.2K | — | 745.1K | PN, OO | Delaware | 2024-02-12 | ↗ |
| 23 | STATE STREET CORPORATION | 708.2K | 5.48% | — | 683.7K | — | 708.2K | HC | — | 2022-02-11 | ↗ |
| 24 | Michael Graves | 238.7K | 1.80% | 238.7K | — | 238.7K | 11.00 | IN | — | 2024-02-14 | ↗ |
| 25 | 27-4413262 | — | 0.00% | — | — | — | — | OO | Maryland | 2024-10-09 | ↗ |
| 26 | Park West Asset Management LLC | — | 0.00% | — | — | — | — | IA | (4) Citizenship or Place of Organization | 2022-02-14 | ↗ |
| 27 | Park West Investors Master Fund, Limited | — | 0.00% | — | — | — | — | CO | (4) Citizenship or Place of Organization | 2022-02-14 | ↗ |
| 28 | Peter S. Park | — | 0.00% | — | — | — | — | IN | (4) Citizenship or Place of Organization | 2022-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
2
+0 vs prev Q
New positions
0
Closed positions
0
Increased
0
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | STANLEY-LAMAN GROUP, LTD. | 12.0K +— (+0.0%) | 4.1K -4.3K (-51.3%) | 0.09% +0.000 pp | 0.00% -0.001 pp | USD29.61 -98.9% | 47 qtrs — |
| 2 | ARCHER INVESTMENT CORP | 350.00 +— (+0.0%) | 119.00 -126.0 (-51.4%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD26.31 -98.7% | 13 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.33
Bearish
Ratio by volume
1.30
Neutral
Buys
2
Sells
6
Shares acquired
16.8K
Shares disposed
12.9K
Cash buys
—
Cash sales
—
Net activity
+3,897
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-11-11 | Krawtschuk Christopher | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-02-28 | Tarriff Scott | 10% Owner | F-InKind | D | Common Stock | 2,119 | 6.27 | 13.3K | 460,621 | — | ↗ |
| 2024-02-27 | Tarriff Scott | 10% Owner | A-Award | A | Common Stock | 12,950 | 0.00 | — | 465,894 | — | ↗ |
| 2024-02-27 | Cahill Brian Joseph | Officer | A-Award | A | Common Stock | 3,800 | 0.00 | — | 49,547 | — | ↗ |
| 2024-02-02 | Cahill Brian Joseph | Officer | F-InKind | D | Common Stock | 934 | 5.85 | 5.5K | 45,747 | — | ↗ |
| 2024-01-05 | Tarriff Scott | 10% Owner | F-InKind | D | Common Stock | 4,322 | 5.13 | 22.2K | 541,125 | — | ↗ |
| 2024-01-05 | Cahill Brian Joseph | Officer | F-InKind | D | Common Stock | 735 | 5.13 | 3.8K | 46,681 | — | ↗ |
| 2023-12-21 | Graves Michael | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 293,000 | 5.01 | 1.47M | 293,000 | — | ↗ |
| 2023-12-18 | Cahill Brian Joseph | Officer | F-InKind | D | Common Stock | 452 | 4.76 | 2.2K | 47,416 | — | ↗ |
| 2023-11-02 | Tarriff Scott | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 10,694 | 13.87 | 148.3K | 545,447 | — | ↗ |
| 2023-11-01 | Tarriff Scott | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 10,925 | 13.82 | 151.0K | 556,141 | — | ↗ |
| 2023-10-27 | Graves Michael | Director | M-Exempt | A | Common Stock | 9,360 | 4.94 | 46.2K | 10,360 | — | ↗ |
| 2023-10-03 | Tarriff Scott | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 10,024 | 14.41 | 144.4K | 567,776 | — | ↗ |
| 2023-10-02 | Tarriff Scott | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 9,511 | 15.23 | 144.9K | 577,800 | — | ↗ |
| 2023-05-16 | Tarriff Scott | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 15,000 | 19.98 | 299.7K | 587,311 | — | ↗ |
| 2023-05-15 | Tarriff Scott | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 14,800 | 21.06 | 311.7K | 1,595,134 | — | ↗ |
| 2023-05-12 | Tarriff Scott | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 3,131 | 19.69 | 61.6K | 1,621,803 | — | ↗ |
| 2023-05-11 | Tarriff Scott | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 15,000 | 20.71 | 310.7K | 1,624,934 | — | ↗ |
| 2023-03-07 | Simpson Jennifer K. | Director | A-Award | A | Stock Option (right to buy) | 16,253 | 26.00 | 422.6K | 16,253 | — | ↗ |
| 2023-03-07 | RATOFF STEVEN B | Director | A-Award | A | Stock Option (right to buy) | 16,253 | 26.00 | 422.6K | 16,253 | — | ↗ |
| 2023-03-07 | Graves Michael | Director | A-Award | A | Stock Option (right to buy) | 16,253 | 26.00 | 422.6K | 16,253 | — | ↗ |
| 2023-03-07 | Glenning Robert | Director | A-Award | A | Stock Option (right to buy) | 16,253 | 26.00 | 422.6K | 16,253 | — | ↗ |
| 2023-03-07 | Edlin Richard A. | Director | A-Award | A | Stock Option (right to buy) | 16,253 | 26.00 | 422.6K | 16,253 | — | ↗ |
| 2023-03-07 | BORIO LUCIANA | Director | A-Award | A | Stock Option (right to buy) | 16,253 | 26.00 | 422.6K | 16,253 | — | ↗ |
| 2023-03-01 | Tarriff Scott | Director / Officer / 10% Owner | A-Award | A | Common Stock | 70,900 | 0.00 | — | 1,639,934 | — | ↗ |
| 2023-03-01 | Cahill Brian Joseph | Officer | A-Award | A | Common Stock | 18,500 | 0.00 | — | 47,868 | — | ↗ |
| 2023-02-28 | Tarriff Scott | Director / Officer / 10% Owner | F-InKind | D | Common Stock | 3,113 | 28.00 | 87.2K | 1,569,034 | — | ↗ |
| 2023-02-28 | Cahill Brian Joseph | Officer | F-InKind | D | Common Stock | 718 | 28.00 | 20.1K | 29,368 | — | ↗ |
| 2023-02-02 | Cahill Brian Joseph | Officer | F-InKind | D | Common Stock | 785 | 34.09 | 26.8K | 30,086 | — | ↗ |
| 2023-01-30 | Cahill Brian Joseph | Officer | F-InKind | D | Common Stock | 601 | 33.21 | 20.0K | 30,871 | — | ↗ |
| 2023-01-23 | Tarriff Scott | Officer | F-InKind | D | Common Stock | 3,732 | 33.64 | 125.5K | 1,572,147 | — | ↗ |
| 2023-01-05 | Tarriff Scott | Officer | F-InKind | D | Common Stock | 3,827 | 29.26 | 112.0K | 1,575,879 | — | ↗ |
| 2023-01-05 | Cahill Brian Joseph | Officer | F-InKind | D | Common Stock | 734 | 29.26 | 21.5K | 31,472 | — | ↗ |
| 2022-12-19 | Cahill Brian Joseph | Officer | F-InKind | D | Common Stock | 461 | 30.03 | 13.8K | 32,206 | — | ↗ |
| 2022-09-06 | Edlin Richard A. | Director | S-Sale | D | Common Stock | 6,800 | 30.99 | 210.7K | 22,600 | — | ↗ |
| 2022-02-28 | Tarriff Scott | Director / Officer / 10% Owner | A-Award | A | Common Stock | 34,800 | 0.00 | — | 1,579,706 | — | ↗ |
| 2022-02-28 | Simpson Jennifer K. | Director | A-Award | A | Stock Option (right to buy) | 11,200 | 47.39 | 530.8K | 11,200 | — | ↗ |
| 2022-02-28 | RATOFF STEVEN B | Director | A-Award | A | Stock Option (right to buy) | 11,200 | 47.39 | 530.8K | 11,200 | — | ↗ |
| 2022-02-28 | Moran Michael Shawn | Officer | A-Award | A | Common Stock | 10,400 | 0.00 | — | 32,115 | — | ↗ |
| 2022-02-28 | Graves Michael | Director | A-Award | A | Stock Option (right to buy) | 11,200 | 47.39 | 530.8K | 11,200 | — | ↗ |
| 2022-02-28 | Glenning Robert | Director | A-Award | A | Stock Option (right to buy) | 11,200 | 47.39 | 530.8K | 11,200 | — | ↗ |
| 2022-02-28 | Edlin Richard A. | Director | A-Award | A | Stock Option (right to buy) | 11,200 | 47.39 | 530.8K | 11,200 | — | ↗ |
| 2022-02-28 | Cahill Brian Joseph | Officer | A-Award | A | Common Stock | 8,000 | 0.00 | — | 32,667 | — | ↗ |
| 2022-02-28 | BORIO LUCIANA | Director | A-Award | A | Stock Option (right to buy) | 11,200 | 47.39 | 530.8K | 11,200 | — | ↗ |
| 2022-02-02 | Moran Michael Shawn | Officer | F-InKind | D | Common Stock | 742 | 45.03 | 33.4K | 21,715 | — | ↗ |
| 2022-02-02 | Cahill Brian Joseph | Officer | F-InKind | D | Common Stock | 805 | 45.03 | 36.2K | 24,667 | — | ↗ |
| 2022-01-31 | Moran Michael Shawn | Officer | F-InKind | D | Common Stock | 210 | 45.94 | 9.6K | 22,457 | — | ↗ |
| 2022-01-31 | Cahill Brian Joseph | Officer | F-InKind | D | Common Stock | 626 | 45.94 | 28.8K | 25,472 | — | ↗ |
| 2022-01-07 | Moran Michael Shawn | Officer | F-InKind | D | Common Stock | 90 | 50.63 | 4.6K | 22,667 | — | ↗ |
| 2022-01-07 | Cahill Brian Joseph | Officer | F-InKind | D | Common Stock | 263 | 50.63 | 13.3K | 26,098 | — | ↗ |
| 2022-01-05 | Moran Michael Shawn | Officer | F-InKind | D | Common Stock | 1,511 | 50.69 | 76.6K | 22,757 | — | ↗ |
| 2022-01-05 | Cahill Brian Joseph | Officer | F-InKind | D | Common Stock | 738 | 50.69 | 37.4K | 26,361 | — | ↗ |
| 2021-12-20 | Cahill Brian Joseph | Officer | F-InKind | D | Common Stock | 467 | 55.42 | 25.9K | 27,099 | — | ↗ |
| 2021-09-27 | Moran Michael Shawn | Officer | — | D | Common Stock | 0 | 0.00 | — | 24,268 | — | ↗ |
| 2021-04-28 | BORIO LUCIANA | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-04-08 | RATOFF STEVEN B | Director | M-Exempt | A | Common Stock | 2,340 | 8.78 | 20.5K | 22,684 | — | ↗ |
| 2021-04-01 | Tarriff Scott | Director / Officer / 10% Owner | M-Exempt | A | Common Stock | 31,201 | 8.78 | 273.9K | 1,561,184 | — | ↗ |
| 2021-02-23 | Tarriff Scott | Director / Officer / 10% Owner | G-Gift | D | Common Stock | 16,340 | 0.00 | — | 1,529,983 | — | ↗ |
| 2021-02-02 | Simpson Jennifer K. | Director | A-Award | A | Stock Option (right to buy) | 13,500 | 49.32 | 665.8K | 13,500 | — | ↗ |
| 2021-02-02 | RATOFF STEVEN B | Director | A-Award | A | Stock Option (right to buy) | 13,500 | 49.32 | 665.8K | 13,500 | — | ↗ |
| 2021-02-02 | Pernock David | Officer | A-Award | A | Common Stock | 9,700 | 0.00 | — | 54,625 | — | ↗ |
| 2021-02-02 | Ng-Cashin Judith | Officer | A-Award | A | Common Stock | 2,000 | 0.00 | — | 2,000 | — | ↗ |
| 2021-02-02 | Graves Michael | Director | A-Award | A | Stock Option (right to buy) | 13,500 | 49.32 | 665.8K | 13,500 | — | ↗ |
| 2021-02-02 | Glenning Robert | Director | A-Award | A | Stock Option (right to buy) | 13,500 | 49.32 | 665.8K | 13,500 | — | ↗ |
| 2021-02-02 | Edlin Richard A. | Director | A-Award | A | Stock Option (right to buy) | 13,500 | 49.32 | 665.8K | 13,500 | — | ↗ |
| 2021-02-02 | Cahill Brian Joseph | Officer | A-Award | A | Common Stock | 8,900 | 0.00 | — | 27,566 | — | ↗ |
| 2021-01-29 | Cahill Brian Joseph | Officer | F-InKind | D | Common Stock | 637 | 46.67 | 29.7K | 18,666 | — | ↗ |
| 2021-01-23 | Tarriff Scott | Director / Officer / 10% Owner | F-InKind | D | Common Stock | 4,631 | 47.70 | 220.9K | 1,546,323 | — | ↗ |
| 2021-01-23 | Pernock David | Officer | F-InKind | D | Common Stock | 1,892 | 47.70 | 90.2K | 44,925 | — | ↗ |
| 2021-01-07 | Pernock David | Officer | F-InKind | D | Common Stock | 906 | 50.97 | 46.2K | 46,817 | — | ↗ |
| 2021-01-07 | Cahill Brian Joseph | Officer | F-InKind | D | Common Stock | 237 | 50.97 | 12.1K | 14,303 | — | ↗ |
| 2021-01-05 | Pernock David | Officer | F-InKind | D | Common Stock | 2,088 | 50.02 | 104.4K | 47,723 | — | ↗ |
| 2021-01-05 | Cahill Brian Joseph | Officer | F-InKind | D | Common Stock | 746 | 50.02 | 37.3K | 14,540 | — | ↗ |
| 2020-12-18 | Cahill Brian Joseph | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 10,000 | 48.09 | 480.9K | 10,000 | — | ↗ |
| 2020-10-29 | Ng-Cashin Judith | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-10-29 | Cahill Brian Joseph | Officer | — | D | Employee Stock Option (right to buy) | 12,500 | 59.14 | 739.3K | 0 | — | ↗ |
| 2020-02-28 | RATOFF STEVEN B | Director | M-Exempt | D | Stock Option (right to buy) | 2,340 | 8.78 | 20.5K | 0 | — | ↗ |
| 2020-01-23 | Tarriff Scott | Director / Officer / 10% Owner | F-InKind | D | Common Stock | 7,548 | 57.98 | 437.6K | 1,550,954 | — | ↗ |
| 2020-01-23 | Pernock David | Officer | F-InKind | D | Common Stock | 1,793 | 57.98 | 104.0K | 49,811 | — | ↗ |
| 2020-01-23 | Meyers Pete A. | Officer | F-InKind | D | Common Stock | 1,653 | 57.98 | 95.8K | 43,615 | — | ↗ |
| 2020-01-23 | Hepner Adrian | Officer | F-InKind | D | Common Stock | 1,630 | 57.98 | 94.5K | 48,784 | — | ↗ |
| 2020-01-07 | Pernock David | Officer | F-InKind | D | Common Stock | 904 | 57.38 | 51.9K | 51,604 | — | ↗ |
| 2020-01-07 | Meyers Pete A. | Officer | F-InKind | D | Common Stock | 632 | 57.38 | 36.3K | 45,268 | — | ↗ |
| 2020-01-07 | Hepner Adrian | Officer | F-InKind | D | Common Stock | 815 | 57.38 | 46.8K | 50,414 | — | ↗ |
| 2020-01-05 | Tarriff Scott | Director / Officer / 10% Owner | A-Award | A | Common Stock | 58,300 | 0.00 | — | 1,558,502 | — | ↗ |
| 2020-01-05 | Simpson Jennifer K. | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 59.80 | 598.0K | 10,000 | — | ↗ |
| 2020-01-05 | RATOFF STEVEN B | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 59.80 | 598.0K | 10,000 | — | ↗ |
| 2020-01-05 | Pernock David | Officer | A-Award | A | Common Stock | 21,500 | 0.00 | — | 52,508 | — | ↗ |
| 2020-01-05 | Meyers Pete A. | Officer | A-Award | A | Common Stock | 19,500 | 0.00 | — | 45,900 | — | ↗ |
| 2020-01-05 | Hepner Adrian | Officer | A-Award | A | Common Stock | 24,000 | 0.00 | — | 51,229 | — | ↗ |
| 2020-01-05 | Graves Michael | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 59.80 | 598.0K | 10,000 | — | ↗ |
| 2020-01-05 | Glenning Robert | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 59.80 | 598.0K | 10,000 | — | ↗ |
| 2020-01-05 | Edlin Richard A. | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 59.80 | 598.0K | 10,000 | — | ↗ |
| 2019-10-25 | Hudson Executive Capital LP | Director | S-Sale | D | Common Stock | 15,437 | 63.57 | 981.3K | 732,777 | — | ↗ |
| 2019-10-24 | Hudson Executive Capital LP | Director | S-Sale | D | Common Stock | 1,494 | 62.53 | 93.4K | 748,214 | — | ↗ |
| 2019-10-23 | Hudson Executive Capital LP | Director | S-Sale | D | Common Stock | 200 | 62.58 | 12.5K | 749,708 | — | ↗ |
| 2019-10-22 | Hudson Executive Capital LP | Director | S-Sale | D | Common Stock | 6,567 | 62.68 | 411.6K | 749,908 | — | ↗ |
| 2019-10-21 | Hudson Executive Capital LP | Director | S-Sale | D | Common Stock | 3,849 | 62.56 | 240.8K | 756,475 | — | ↗ |
| 2019-10-18 | Hudson Executive Capital LP | Director | S-Sale | D | Common Stock | 1,600 | 62.61 | 100.2K | 760,324 | — | ↗ |
| 2019-10-17 | Hudson Executive Capital LP | Director | S-Sale | D | Common Stock | 13,842 | 62.58 | 866.2K | 761,924 | — | ↗ |
| 2019-10-16 | Hudson Executive Capital LP | Director | S-Sale | D | Common Stock | 102 | 62.50 | 6.4K | 775,766 | — | ↗ |
| 2019-10-15 | Hudson Executive Capital LP | Director | S-Sale | D | Common Stock | 3,909 | 62.63 | 244.8K | 775,868 | — | ↗ |
| 2019-10-11 | Hudson Executive Capital LP | Director | S-Sale | D | Common Stock | 16,300 | 60.39 | 984.4K | 779,777 | — | ↗ |
| 2019-10-10 | Hudson Executive Capital LP | Director | S-Sale | D | Common Stock | 7,829 | 60.16 | 471.0K | 796,077 | — | ↗ |
| 2019-10-08 | Simpson Jennifer K. | Director | A-Award | A | Stock option (right to buy) | 10,000 | 58.88 | 588.8K | 10,000 | — | ↗ |
| 2019-10-08 | Hudson Executive Capital LP | Director | S-Sale | D | Common Stock | 1,558 | 60.03 | 93.5K | 803,906 | — | ↗ |
| 2019-10-07 | Hudson Executive Capital LP | Director | S-Sale | D | Common Stock | 4,901 | 60.11 | 294.6K | 805,464 | — | ↗ |
| 2019-09-17 | Hudson Executive Capital LP | Director | S-Sale | D | Common Stock | 100 | 60.00 | 6.0K | 810,365 | — | ↗ |
| 2019-09-12 | Hudson Executive Capital LP | Director | S-Sale | D | Common Stock | 200 | 60.07 | 12.0K | 810,465 | — | ↗ |
| 2019-09-11 | Hudson Executive Capital LP | Director | S-Sale | D | Common Stock | 1,112 | 60.06 | 66.8K | 810,665 | — | ↗ |
| 2019-08-28 | Simpson Jennifer K. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-05-10 | Braunstein Douglas L | Director | S-Sale | D | Common Stock | 100,000 | 56.14 | 5.61M | 811,777 | — | ↗ |
| 2019-05-09 | Braunstein Douglas L | Director | S-Sale | D | Common Stock | 59,223 | 57.95 | 3.43M | 911,777 | — | ↗ |
| 2019-04-01 | Tarriff Scott | Director / Officer / 10% Owner | S-Sale | D | Commn Stock | 24,975 | 50.15 | 1.25M | 1,500,202 | — | ↗ |
| 2019-03-05 | FLAUM SANDER A | Director | M-Exempt | A | Common Stock | 2,340 | 4.04 | 9.5K | 13,714 | — | ↗ |
| 2019-03-04 | RATOFF STEVEN B | Director | M-Exempt | D | Stock Option (right to buy) | 2,340 | 4.04 | 9.5K | 0 | — | ↗ |
| 2019-03-01 | Tarriff Scott | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 12,000 | 50.51 | 606.1K | 1,537,605 | — | ↗ |
| 2019-02-01 | Tarriff Scott | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 29,185 | 41.52 | 1.21M | 1,550,505 | — | ↗ |
| 2019-01-23 | Tarriff Scott | Director / Officer / 10% Owner | A-Award | A | Employee Stock Option (right to buy) | 137,200 | 42.40 | 5.82M | 137,200 | — | ↗ |
| 2019-01-23 | RATOFF STEVEN B | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 42.40 | 424.0K | 10,000 | — | ↗ |
| 2019-01-23 | Pernock David | Officer | A-Award | A | Employee Stock Option (right to buy) | 46,600 | 42.40 | 1.98M | 46,600 | — | ↗ |
| 2019-01-23 | Meyers Pete A. | Officer | A-Award | A | Employee Stock Option (right to buy) | 43,200 | 42.40 | 1.83M | 43,200 | — | ↗ |
| 2019-01-23 | Hepner Adrian | Officer | A-Award | A | Common Stock | 19,000 | 0.00 | — | 27,229 | — | ↗ |
| 2019-01-23 | Graves Michael | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 42.40 | 424.0K | 10,000 | — | ↗ |
| 2019-01-23 | Glenning Robert | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 42.40 | 424.0K | 10,000 | — | ↗ |
| 2019-01-23 | FLAUM SANDER A | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 42.40 | 424.0K | 10,000 | — | ↗ |
| 2019-01-23 | Edlin Richard A. | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 42.40 | 424.0K | 10,000 | — | ↗ |
| 2019-01-23 | Braunstein Douglas L | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 42.40 | 424.0K | 10,000 | — | ↗ |
| 2019-01-07 | Pernock David | Officer | F-InKind | D | Common Stock | 858 | 41.33 | 35.5K | 10,108 | — | ↗ |
| 2019-01-07 | Meyers Pete A. | Officer | F-InKind | D | Common Stock | 600 | 41.33 | 24.8K | 7,100 | — | ↗ |
| 2019-01-07 | Hepner Adrian | Officer | F-InKind | D | Common Stock | 771 | 41.33 | 31.9K | 8,229 | — | ↗ |
| 2019-01-03 | Tarriff Scott | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 10,597 | 39.04 | 413.7K | 1,524,362 | — | ↗ |
| 2019-01-02 | Tarriff Scott | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 6,500 | 39.30 | 255.5K | 1,543,459 | — | ↗ |
| 2018-06-28 | Tarriff Scott | Director / Officer | M-Exempt | A | Common Stock | 124,804 | 4.04 | 504.2K | 1,549,959 | — | ↗ |
| 2018-03-30 | Tarriff Scott | Director / Officer | M-Exempt | A | Common Stock | 113,104 | 4.04 | 456.9K | 1,483,050 | — | ↗ |
| 2018-03-06 | FLAUM SANDER A | Director | S-Sale | D | Common Stock | 2,340 | 53.94 | 126.2K | 11,374 | — | ↗ |
| 2018-03-05 | FLAUM SANDER A | Director | M-Exempt | A | Common Stock | 2,340 | 0.90 | 2.1K | 13,714 | — | ↗ |
| 2018-01-07 | Tarriff Scott | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 157,000 | 59.14 | 9.28M | 157,000 | — | ↗ |
| 2018-01-07 | RATOFF STEVEN B | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 59.14 | 591.4K | 10,000 | — | ↗ |
| 2018-01-07 | Pernock David | Officer | A-Award | A | Common Stock | 10,000 | 0.00 | — | 10,966 | — | ↗ |
| 2018-01-07 | Meyers Pete A. | Officer | A-Award | A | Performance Stock Unit | 21,000 | 0.00 | — | 21,000 | — | ↗ |
| 2018-01-07 | Krill Steven L. | Officer | A-Award | A | Performance Stock Unit | 9,000 | 0.00 | — | 9,000 | — | ↗ |
| 2018-01-07 | Hepner Adrian | Officer | A-Award | A | Common Stock | 9,000 | 0.00 | — | 9,000 | — | ↗ |
| 2018-01-07 | Graves Michael | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 59.14 | 591.4K | 10,000 | — | ↗ |
| 2018-01-07 | Glenning Robert | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 59.14 | 591.4K | 10,000 | — | ↗ |
| 2018-01-07 | FLAUM SANDER A | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 59.14 | 591.4K | 10,000 | — | ↗ |
| 2018-01-07 | Edlin Richard A. | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 59.14 | 591.4K | 10,000 | — | ↗ |
| 2018-01-07 | Braunstein Douglas L | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 59.14 | 591.4K | 10,000 | — | ↗ |
| 2017-12-18 | RATOFF STEVEN B | Director | M-Exempt | A | Common Stock | 2,340 | 0.90 | 2.1K | 15,664 | — | ↗ |
| 2017-08-16 | Meyers Pete A. | Officer | P-Purchase | A | Common Stock | 350 | 55.45 | 19.4K | 700 | — | ↗ |
| 2017-08-09 | Braunstein Douglas L | Director | P-Purchase | A | Common Stock | 3,610 | 48.06 | 173.5K | 954,210 | — | ↗ |
| 2017-06-12 | Meyers Pete A. | Officer | P-Purchase | A | Common Stock | 350 | 71.49 | 25.0K | 350 | — | ↗ |
| 2017-05-19 | Pernock David | Officer | P-Purchase | A | Common Stock | 255 | 79.69 | 20.3K | 966 | — | ↗ |
| 2017-05-16 | Pernock David | Officer | P-Purchase | A | Common Stock | 200 | 82.24 | 16.4K | 711 | — | ↗ |
| 2017-05-15 | ProQuest Investments IV, L.P. | 10% Owner | J-Other | A | Common Stock $0.001 par value | 149,107 | 0.00 | — | 172,381 | — | ↗ |
| 2017-05-15 | Meyers Pete A. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 50,000 | 82.30 | 4.12M | 50,000 | — | ↗ |
| 2017-04-25 | ProQuest Investments IV, L.P. | 10% Owner | M-Exempt | A | Common Stock $0.001 par value | 2,340 | 0.90 | 2.1K | 9,117 | — | ↗ |
| 2017-04-03 | ProQuest Investments IV, L.P. | 10% Owner | S-Sale | D | Common Stock $0.001 par value | 61,420 | 83.13 | 5.11M | 3,584,087 | — | ↗ |
| 2017-03-31 | ProQuest Investments IV, L.P. | 10% Owner | S-Sale | D | Common Stock $0.001 par value | 23,689 | 83.02 | 1.97M | 3,645,507 | — | ↗ |
| 2017-03-30 | ProQuest Investments IV, L.P. | 10% Owner | S-Sale | D | Common Stock $0.001 par value | 6,223 | 83.00 | 516.5K | 3,669,196 | — | ↗ |
| 2017-03-29 | ProQuest Investments IV, L.P. | 10% Owner | S-Sale | D | Common Stock $0.001 par value | 1,600 | 83.01 | 132.8K | 23,274 | — | ↗ |
| 2017-03-28 | ProQuest Investments IV, L.P. | 10% Owner | S-Sale | D | Common Stock $0.001 par value | 6,182 | 83.02 | 513.2K | 3,734,174 | — | ↗ |
| 2017-03-27 | ProQuest Investments IV, L.P. | 10% Owner | S-Sale | D | Common Stock $0.001 par value | 400 | 83.00 | 33.2K | 7,277 | — | ↗ |
| 2017-03-23 | ProQuest Investments IV, L.P. | 10% Owner | S-Sale | D | Common Stock $0.001 par value | 700 | 83.01 | 58.1K | 3,778,087 | — | ↗ |
| 2017-03-23 | Krill Steven L. | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 2,025 | 12.67 | 25.7K | 4,850 | — | ↗ |
| 2017-03-22 | Krill Steven L. | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 2,077 | 12.67 | 26.3K | 6,875 | — | ↗ |
| 2017-03-22 | Edlin Richard A. | Director | P-Purchase | A | Common Stock | 6,000 | 79.44 | 476.6K | 29,400 | — | ↗ |
| 2017-03-21 | ProQuest Investments IV, L.P. | 10% Owner | S-Sale | D | Common Stock $0.001 par value | 500 | 83.10 | 41.6K | 3,778,787 | — | ↗ |
| 2017-03-21 | Pernock David | Officer | P-Purchase | A | Common Stock | 61 | 83.98 | 5.1K | 511 | — | ↗ |
| 2017-03-20 | ProQuest Investments IV, L.P. | 10% Owner | S-Sale | D | Common Stock $0.001 par value | 51,883 | 82.10 | 4.26M | 3,779,287 | — | ↗ |
| 2017-03-17 | ProQuest Investments IV, L.P. | 10% Owner | S-Sale | D | Common Stock $0,001 par value | 38,997 | 82.01 | 3.20M | 3,831,170 | — | ↗ |
| 2017-03-17 | Edlin Richard A. | Director | — | D | Options (Right to Buy) | 2,340 | 8.78 | 20.5K | 0 | — | ↗ |
| 2017-03-16 | ProQuest Investments IV, L.P. | 10% Owner | S-Sale | D | Common Stock $0.001 par value | 9,120 | 82.08 | 748.6K | 3,870,167 | — | ↗ |
| 2017-03-09 | Pernock David | Officer | P-Purchase | A | Common Stock | 450 | 77.84 | 35.0K | 450 | — | ↗ |
| 2017-01-04 | Tarriff Scott | Director / Officer | A-Award | A | Stock Option (right to buy) | 200,900 | 84.92 | 17.06M | 200,900 | — | ↗ |
| 2017-01-04 | RIGGS DAVID E | Officer | A-Award | A | Stock Option (right to buy) | 40,000 | 84.92 | 3.40M | 40,000 | — | ↗ |
| 2017-01-04 | RATOFF STEVEN B | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 84.92 | 849.2K | 10,000 | — | ↗ |
| 2017-01-04 | ProQuest Investments IV, L.P. | 10% Owner | S-Sale | D | Common Stock $0.001 par value | 65,114 | 85.16 | 5.55M | 3,879,287 | — | ↗ |
| 2017-01-04 | Pernock David | Officer | A-Award | A | Stock Option (right to buy) | 90,000 | 84.92 | 7.64M | 90,000 | — | ↗ |
| 2017-01-04 | Krill Steven L. | Officer | A-Award | A | Stock Option (right to buy) | 42,000 | 84.92 | 3.57M | 42,000 | — | ↗ |
| 2017-01-04 | Hepner Adrian | Officer | A-Award | A | Stock Option (right to buy) | 67,200 | 84.92 | 5.71M | 67,200 | — | ↗ |
| 2017-01-04 | Graves Michael | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 84.92 | 849.2K | 10,000 | — | ↗ |
| 2017-01-04 | Glenning Robert | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 84.92 | 849.2K | 10,000 | — | ↗ |
| 2017-01-04 | FLAUM SANDER A | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 84.92 | 849.2K | 10,000 | — | ↗ |
| 2017-01-04 | Braunstein Douglas L | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 84.92 | 849.2K | 10,000 | — | ↗ |
| 2016-12-23 | Krill Steven L. | Officer | M-Exempt | A | Common Stock | 5,127 | 46.09 | 236.3K | 5,127 | — | ↗ |
| 2016-12-22 | Krill Steven L. | Officer | S-Sale | D | Common Stock | 5,126 | 76.78 | 393.6K | 0 | — | ↗ |
| 2016-12-21 | Krill Steven L. | Officer | M-Exempt | D | Stock Option (right to buy) | 2,683 | 12.63 | 33.9K | 20,000 | — | ↗ |
| 2016-12-20 | Krill Steven L. | Officer | M-Exempt | D | Stock Option (right to buy) | 10,000 | 12.63 | 126.3K | 22,683 | — | ↗ |
| 2016-12-19 | Krill Steven L. | Officer | M-Exempt | D | Stock Option (right to buy) | 7,317 | 12.63 | 92.4K | 32,683 | — | ↗ |
| 2016-12-15 | Krill Steven L. | Officer | M-Exempt | D | Stock Option (right to buy) | 6,270 | 12.67 | 79.4K | 11,635 | — | ↗ |
| 2016-12-13 | RATOFF STEVEN B | Director | S-Sale | D | Common Stock | 8,700 | 75.00 | 652.5K | 13,324 | — | ↗ |
| 2016-12-13 | Krill Steven L. | Officer | M-Exempt | A | Common Stock | 10,000 | 4.42 | 44.2K | 10,000 | — | ↗ |
| 2016-12-12 | RATOFF STEVEN B | Director | S-Sale | D | Common Stock | 1,300 | 75.07 | 97.6K | 22,024 | — | ↗ |
| 2016-11-30 | Krill Steven L. | Officer | M-Exempt | A | Common Stock | 1,950 | 8.78 | 17.1K | 1,950 | — | ↗ |
| 2016-11-28 | FLAUM SANDER A | Director | S-Sale | D | Common Stock | 5,000 | 78.66 | 393.3K | 11,374 | — | ↗ |
| 2016-11-23 | Krill Steven L. | Officer | M-Exempt | D | Stock Option (right to buy) | 200 | 8.78 | 1.8K | 2,530 | — | ↗ |
| 2016-11-11 | ProQuest Investments IV, L.P. | 10% Owner | S-Sale | D | Common Stock $0.001 par value | 15,551 | 85.00 | 1.32M | 3,944,401 | — | ↗ |
| 2016-11-10 | ProQuest Investments IV, L.P. | 10% Owner | S-Sale | D | Common Stock $0.001 par value | 167 | 86.00 | 14.4K | 3,961,752 | — | ↗ |
| 2016-11-09 | ProQuest Investments IV, L.P. | 10% Owner | S-Sale | D | Common Stock $0.001 par value | 19,581 | 79.24 | 1.55M | 4,080,206 | — | ↗ |
Executive team
Top executives
Shares Outstanding
12.99M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2022 | Scott Tarriff President, Chief Executive Officer, Director | 848.9K | — | 9.01M | — | 636.7K | 23.7K | 10.52M | 85.65% | ↗ |
| 2 | 2022 | Michael Moran Former Chief Commercial Officer | 277.7K | — | 2.31M | — | — | 20.6K | 2.61M | 88.56% | ↗ |
| 3 | 2022 | Brian Cahill Chief Financial Officer | 394.9K | — | 1.79M | — | 177.8K | 33.3K | 2.49M | 71.68% | ↗ |
| 4 | 2021 | Scott Tarriff President, Chief Executive Officer, Director | 815.9K | — | 4.29M | — | 1.34M | 23.1K | 6.47M | 66.35% | ↗ |
| 5 | 2021 | David Pernock Former President and Chief Operating Officer | 602.0K | — | 1.17M | — | — | 1.23M | 3.00M | 38.97% | ↗ |
| 6 | 2021 | Michael Moran Former Chief Commercial Officer | 424.3K | — | 987.4K | — | 418.5K | 27.7K | 1.86M | 53.14% | ↗ |
| 7 | 2021 | Michael Moran Chief Commercial Officer | 424.3K | — | 987.4K | — | 418.5K | 27.7K | 1.86M | 53.14% | ↗ |
| 8 | 2021 | Brian Cahill Chief Financial Officer | 380.0K | — | 1.07M | — | 373.9K | 30.0K | 1.86M | 57.75% | ↗ |
| 9 | 2021 | Judith Ng-Cashin, M.D. Former Executive Vice President and Chief Medical Officer | 465.9K | — | 240.8K | — | — | 243.7K | 950.4K | 25.34% | ↗ |
| 10 | 2020 | Scott Tarriff Chief Executive Officer, Director | 822.1K | — | 3.49M | 4.58M | 554.8K | 22.6K | 9.47M | 85.22% | ↗ |
| 11 | 2020 | Scott Tarriff President, Chief Executive Officer, Director | 822.1K | — | 3.49M | 4.58M | 554.8K | 22.6K | 9.47M | 85.22% | ↗ |
| 12 | 2020 | Pete A. Meyers Former Chief Financial Officer | 419.0K | — | 1.17M | 1.51M | — | 728.8K | 3.82M | 69.98% | ↗ |
| 13 | 2020 | David Pernock President and Chief Operating Officer | 606.5K | — | 1.29M | 1.60M | 245.6K | 44.2K | 3.79M | 76.33% | ↗ |
| 14 | 2020 | David Pernock Former President and Chief Operating Officer | 606.5K | — | 1.29M | 1.60M | 245.6K | 44.2K | 3.79M | 76.33% | ↗ |
| 15 | 2020 | Adrian J. Hepner, M.D., Ph.D. Former Executive Vice President and Chief Medical Officer | 313.0K | — | 1.43M | 1.73M | — | 19.7K | 3.50M | 90.49% | ↗ |
| 16 | 2020 | Brian Cahill Chief Financial Officer | 334.9K | — | 659.0K | 655.1K | 136.1K | 29.3K | 1.81M | 72.43% | ↗ |
| 17 | 2020 | Judith Ng-Cashin, M.D. Former Executive Vice President and Chief Medical Officer | 70.9K | — | — | 832.8K | 43.1K | 4.3K | 951.0K | 87.57% | ↗ |
| 18 | 2020 | Judith Ng-Cashin, M.D. Chief Medical Officer | 70.9K | — | — | 832.8K | 43.1K | 4.3K | 951.0K | 87.57% | ↗ |
| 19 | 2019 | Scott Tarriff President, Chief Executive Officer, Director | 769.4K | — | 2.60M | 2.96M | 1.54M | 21.0K | 7.88M | 70.46% | ↗ |
| 20 | 2019 | Scott Tarriff Chief Executive Officer, Director | 769.4K | — | 2.60M | 2.96M | 1.54M | 21.0K | 7.88M | 70.46% | ↗ |
| 21 | 2019 | David Pernock Former President and Chief Operating Officer | 567.6K | — | 886.2K | 1.00M | 681.1K | 33.8K | 3.17M | 59.57% | ↗ |
| 22 | 2019 | David Pernock President and Chief Operating Officer | 567.6K | — | 886.2K | 1.00M | 681.1K | 33.8K | 3.17M | 59.57% | ↗ |
| 23 | 2019 | Pete A. Meyers Chief Financial Officer | 412.0K | — | 818.3K | 930.5K | 494.4K | 28.4K | 2.68M | 65.17% | ↗ |
| 24 | 2019 | Pete A. Meyers Former Chief Financial Officer | 412.0K | — | 818.3K | 930.5K | 494.4K | 28.4K | 2.68M | 65.17% | ↗ |
| 25 | 2019 | Adrian J. Hepner, M.D., Ph.D. Former Executive Vice President and Chief Medical Officer | 424.4K | — | 805.6K | 915.5K | 509.2K | 25.6K | 2.68M | 64.21% | ↗ |
| 26 | 2019 | Adrian J. Hepner, M.D., Ph.D. Executive Vice President and Chief Medical Officer | 424.4K | — | 805.6K | 915.5K | 509.2K | 25.6K | 2.68M | 64.21% | ↗ |
| 27 | 2018 | Scott Tarriff Chief Executive Officer, Director | 769.4K | — | 5.68M | 4.20M | 654.0K | 19.2K | 11.32M | 87.26% | ↗ |
| 28 | 2018 | David Pernock President and Chief Operating Officer | 540.7K | — | 1.49M | 1.34M | 289.5K | 14.5K | 3.68M | 77.02% | ↗ |
| 29 | 2018 | Adrian J. Hepner, M.D., Ph.D. Former Executive Vice President and Chief Medical Officer | 424.4K | — | 1.34M | 1.15M | 203.7K | 12.5K | 3.13M | 79.57% | ↗ |
| 30 | 2018 | Adrian J. Hepner, M.D., Ph.D. Executive Vice President and Chief Medical Officer | 424.4K | — | 1.34M | 1.15M | 203.7K | 12.5K | 3.13M | 79.57% | ↗ |
| 31 | 2018 | Pete A. Meyers Chief Financial Officer | 412.0K | — | 1.05M | 989.8K | 210.1K | 16.6K | 2.67M | 76.11% | ↗ |
| 32 | 2018 | Pete A. Meyers Former Chief Financial Officer | 412.0K | — | 1.05M | 989.8K | 210.1K | 16.6K | 2.67M | 76.11% | ↗ |
| 33 | 2018 | Steven L. Krill, Ph.D. Former Executive Vice President and Chief Scientific Officer | — | — | 448.0K | 401.3K | — | 254.6K | 1.10M | 76.93% | ↗ |
| 34 | 2017 | Scott Tarriff Chief Executive Officer, Director | 747.0K | 523.0K | — | 6.74M | — | 29.1K | 8.04M | 83.85% | ↗ |
| 35 | 2017 | David Pernock President and Chief Operating Officer | 515.0K | 216.0K | — | 3.02M | — | 13.1K | 3.76M | 80.23% | ↗ |
| 36 | 2017 | David Pernock President and Chief Commercial Officer | 515.0K | 216.0K | — | 3.02M | — | 13.1K | 3.76M | 80.23% | ↗ |
| 37 | 2017 | Adrian J. Hepner, M.D., Ph.D. Executive Vice President and Chief Medical Officer | 412.0K | 136.0K | — | 2.26M | — | 28.8K | 2.83M | 79.64% | ↗ |
| 38 | 2017 | Steven L. Krill, Ph.D. Former Executive Vice President and Chief Scientific Officer | 412.0K | 99.0K | — | 1.41M | — | 25.9K | 1.95M | 72.42% | ↗ |
| 39 | 2017 | Steven L. Krill, Ph.D. Executive Vice President and Chief Scientific Officer | 412.0K | 99.0K | — | 1.41M | — | 25.9K | 1.95M | 72.42% | ↗ |
| 40 | 2017 | Pete A. Meyers Chief Financial Officer | 238.5K | 112.0K | — | 1.53M | — | 15.8K | 1.90M | 80.70% | ↗ |
| 41 | 2017 | David E. Riggs Former Chief Financial Officer | 410.7K | — | — | 1.34M | — | 26.6K | 1.78M | 75.43% | ↗ |
| 42 | 2016 | Scott Tarriff Chief Executive Officer, Director | 725.0K | 1.09M | — | 5.30M | — | 43.2K | 7.15M | 74.05% | ↗ |
| 43 | 2016 | Adrian J. Hepner, M.D., Ph.D. Executive Vice President and Chief Medical Officer | 400.0K | 830.0K | — | 1.83M | — | 38.4K | 3.10M | 59.03% | ↗ |
| 44 | 2016 | Adrian J. Hepner , M.D., Ph.D. Executive Vice President and Chief Medical Officer | 400.0K | 830.0K | — | 1.83M | — | 38.4K | 3.10M | 59.03% | ↗ |
| 45 | 2016 | David E. Riggs Former Chief Financial Officer | 435.0K | 261.0K | — | 1.83M | — | 27.1K | 2.55M | 71.65% | ↗ |
| 46 | 2016 | David E. Riggs Chief Financial Officer | 435.0K | 261.0K | — | 1.83M | — | 27.1K | 2.55M | 71.65% | ↗ |
| 47 | 2016 | Steven L. Krill, Ph.D. Former Executive Vice President and Chief Scientific Officer | 400.0K | 216.0K | — | 1.83M | — | 30.6K | 2.47M | 73.86% | ↗ |
| 48 | 2016 | Steven L. Krill, Ph.D. Executive Vice President and Chief Scientific Officer | 400.0K | 216.0K | — | 1.83M | — | 30.6K | 2.47M | 73.86% | ↗ |
| 49 | 2015 | Scott Tarriff Chief Executive Officer, Director | 499.2K | 375.0K | — | 1.91M | — | 45.7K | 2.83M | 67.45% | ↗ |
| 50 | 2015 | Scott Tarriff President and Chief Executive Officer, | 499.2K | 375.0K | — | 1.91M | — | 45.7K | 2.83M | 67.45% | ↗ |
| 51 | 2015 | Steven L. Krill, Ph.D. Executive Vice President and Chief Scientific Officer | 318.8K | 146.0K | — | 1.09M | — | 15.9K | 1.57M | 69.34% | ↗ |
| 52 | 2015 | Steven L. Krill, Ph.D. Executive Vice President and Chief | 318.8K | 146.0K | — | 1.09M | — | 15.9K | 1.57M | 69.34% | ↗ |
| 53 | 2015 | David E. Riggs Chief Financial Officer | 309.8K | 140.0K | — | 858.4K | — | 16.6K | 1.32M | 64.79% | ↗ |
| 54 | 2015 | David E. Riggs Former Chief Financial Officer | 309.8K | 140.0K | — | 858.4K | — | 16.6K | 1.32M | 64.79% | ↗ |
| 55 | 2015 | Adrian J. Hepner, M.D., Ph.D. Executive Vice President and Chief Medical Officer | 311.8K | 151.0K | — | 170.1K | — | 56.9K | 689.7K | 24.66% | ↗ |
| 56 | 2015 | Adrian J. Hepner , M.D., Ph.D. Executive Vice President and Chief Medical Officer | 311.8K | 151.0K | — | 170.1K | — | 56.9K | 689.7K | 24.66% | ↗ |
| 57 | 2015 | Adrian Hepner , M.D., Ph.D. Executive Vice President and Chief Medical Officer | 311.8K | 151.0K | — | 170.1K | — | 56.9K | 689.7K | 24.66% | ↗ |
| 58 | 2015 | Paul Bruinenberg , M.D. Former Chief Medical Officer | 71.2K | — | — | 137.0K | — | 136.5K | 344.7K | 39.75% | ↗ |
| 59 | 2014 | Scott Tarriff President and Chief Executive Officer, Director | 449.6K | — | — | 493.6K | — | 38.7K | 975.9K | 50.58% | ↗ |
| 60 | 2014 | Scientific Officer | 302.4K | 42.4K | — | 392.2K | — | 12.3K | 749.2K | 52.35% | ↗ |
| 61 | 2014 | Steven L. Krill, Ph.D. Chief Scientific Officer | 327.4K | 25.0K | — | 392.2K | — | 12.3K | 747.7K | 52.46% | ↗ |
| 62 | 2014 | Scott Tarriff Chief Executive Officer, Director | 146.4K | — | — | — | — | 11.8K | 158.1K | 0.00% | ↗ |
| 63 | 2014 | Scott Tarriff President and Chief Executive Officer, | 146.4K | — | — | — | — | 11.8K | 158.1K | 0.00% | ↗ |
| 64 | 2014 | Paul Bruinenberg , M.D. Former Chief Medical Officer | 89.0K | — | — | — | — | 6.3K | 95.2K | 0.00% | ↗ |
| 65 | 2014 | Steven L. Krill, Ph.D. Executive Vice President and Chief | 82.4K | — | — | — | — | 4.6K | 87.0K | 0.00% | ↗ |
| 66 | 2014 | Steven L. Krill, Ph.D. Executive Vice President and Chief Scientific Officer | 82.4K | — | — | — | — | 4.6K | 87.0K | 0.00% | ↗ |
| 67 | 2014 | David E. Riggs Chief Financial Officer | 81.1K | — | — | — | — | 4.6K | 85.7K | 0.00% | ↗ |
| 68 | 2013 | Scott Tarriff President and Chief Executive Officer, Director | 408.0K | — | — | — | — | 35.7K | 440.6K | 0.00% | ↗ |
| 69 | 2013 | Scientific Officer | 272.6K | 25.0K | — | 116.5K | — | 11.3K | 425.4K | 27.40% | ↗ |
| 70 | 2013 | Steven L. Krill, Ph.D. Chief Scientific Officer | 272.6K | — | — | 116.5K | — | 11.3K | 392.2K | 29.72% | ↗ |
CEO compensation breakdown
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Michael Graves | CEO & Chairman | 160.0K | male |
| Christopher Krawtschuk | Chief Financial Officer and Principal Financial & Accounting Officer | — | male |
| Daniel O'Connor | Executive Vice President, Chief Strategy Officer & Head of Corporate Development | — | male |
| Debra Hussain | Senior Vice President & Head of Commercial | — | female |
| Valentin R. Curt | Senior Vice President of Clinical Drug Development | — | — |
ESG Rating
ESG Score History DRUG MANUFACTURERS - SPECIALTY & GENERIC
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for EGRX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
